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Summary
A single chain glycoprotein with an estimated molecular mass of 160kD (gp160) was previously
identified as a human lung tumor-associated antigen . This tumor marker is shown here to be
associated noncovalently with a second 130-kD protein . Sequential immunoprecipitation studies
ofsurface iodinated lung tumor cell lysates reveal that this beterodimeric complex is indistinguishable
serologically and structurally from the integrinVLA2, found originally on activated T lymphocytes
and platelets. The VLA2-like complex expressed on the lung tumors possesses similar characteristic
Mgt-1 dependent binding of collagen and laminin as observed with VLA-2 on normal cells.
RNA analysis indicates that human lung tumors express at least 20 times more VLA2 ci chain
message than normal adult human lung tissue. The results presented here raise the possibility
that the overproduction ofVLA-2 may be involved in the pathogenesis ofhuman lung tumors
by modulating the invasive and metastatic potential of the tumor.
I
n view of the fact that primary cancers of the lung are the
leading cause of cancer related deaths in men and women
in the United States, it is surprising that there are relatively
few reports on the molecular and functional characterization
of human lung tumor-associated antigens (TAA)l (1-5) .
These reports have provided limited characterizations of the
molecules with regard to structure, and none of these studies
have been able to postulate a possible functional role of the
TAA with respect to tumor pathogenesis . Previous studies
using a mAb, 5E8, derived from the fusion of spleen cells
from mice repeatedly immunized with fresh human lung
tumor biopsy tissue, led to the identification of a cell surface
glycoprotein (gp160) that was associated with a high propor-
tion of various histological types ofhuman lung cancers (6,
7). ThisTAA has been detected on 75-80% of the non-small
cell human lung cancer biopsies and lung tumor cell lines,
and was originally characterized as a single polypeptide chain
with an estimated molecular mass of 160 kD (7), with char-
acteristics and distribution patterns similar to the epidermal
growth factor receptor (8-10) . Our objective here was to char-
acterize this molecule more completely in order to gain some
insight regarding its molecular identity and possible func-
tion . The results presented here establish that gp160 is a subunit
of a heterodimeric complex that is indistinguishable from a
collagen binding integrin, with regard- to subunit structure
and ligand specificity, and that the expression of this mole-
cule is upregulated in non-small cell lung tumors. Adhesion
1 Abbreviations used in this paper : CEA, carcinoembryonic antigen ; gp,
glycoprotein; RctM-yG, rabbit anti-mouse gammaglobulins; TAA, tumor
associated antigen.
molecules such asVLA2 determine the specificity ofcell-to-
cell and cell-to-extracellular matrix associations . They have
provided insights into embryonic development (11, 12) in
normal tissue and cellular invasion and metastasis (13, 14)
of neoplastic tissue. The process of tumor invasion and
metastasis, like that ofnormal embryonic development or the
inflammation and subsequent repair ofdamaged tissue, re-
quires a complex coordinated set of changes in cell-to-cell
and cell-to-substratum interactions (15, 16) . We, therefore,
consider the possibility that the over expression of VLA2
reported here may be directly involved in the pathogenesis
ofnon-small cell primary lung tumors either through effects
on the tumor's ability to invade normal tissue or to metastasize.
Materials and Methods
CellLinesand Tissues.
￿
Human lung cancer cell lines, expressing
or lacking the lung tumor-associated antigen (gp160) used in this
study include A549, a gp160-positive human alveolar carcinoma
cell line (7, 17), and QU-DA a gp160-negative large cell carcinoma
cell line (18), obtained from Dr . Susan P.C . Cole (Dept. ofMicrobi-
ology and Immunology, Queen's University, Kingston, Ontario,
Canada) . Cells were cultured in RPMI 1640 containing 10% FCS
and harvested with 0.05% trypsin and 0.04% EDTA in PBS.
Human primary lung tumor biopsies including adjacent normal
lung tissues, were obtained by surgical biopsy ofpatients from the
Roswell Park Cancer Institute (RPCI) Departments of Thoracic
Surgery and Surgical Oncology.
Monoclonal Antibodies.
￿
mAbs used in this study include 5E8,
a mouse ylu mAb, specific for gp160 (7, 8), 5C7, a mouse ^yltt
mAb that binds to a cell surface molecule found on human adenocar-
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for the at chain of the VLA-2 heterodimer (19), a gift from Dr.
M. E. Hemler (Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA) .
Immunoprecipitation .
￿
A549 cells were surface iodinated as de-
scribed previously (20, 21) . The labeled cells or membrane frac-
tions were washed in PBS and then lysed in PBS containing 1%
NP-40and1mMPMSF. After centrifugation (30,000g for 15 min),
the soluble material from the cell lysate was immunoprecipitated
according to the following protocol . 20 wl ofeither normal mouse
gammaglobulin (NMyG) or mAb (at aconcentration of 0.8-1.0
mg/ml) was added to 300-400wl of the radiolabeled lysates. After
a 12-16-h incubation at 4°C, 10 ptl of rabbit anti-mouse gam-
maglobulin (RaMyG) antisera (2 mg/nil)was addedandincubated
at 4°C for 15 min . Precipitation of the immune complex was ac-
complishedby the addition of 150pl ofa10% suspension ofStaph-
ylococcus aureus microorganisms .
In some cases the supernatants of radiolabeled cell lysates were
subjected to asecond immunoprecipitation. In these sequential im-
munoprecipitation protocols, the labeled cell lysate was first im-
munoprecipitated by onemAbfollowed byRaMyG andS. aureus
and after centrifugation the supernatant of the labeled lysate was
reprecipitated with a second mAb followed by RaMyG and S .
aureus . Some labeled cell lysateswere subjected to a pulse of either
high or lowpH andthen adjusted topH 7.0 (with NaOH or HCI)
before immunoprecipitation .
Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis (SDS-
PACE) Analysis. One-dimensional, discontinuous, SDS-PAGE
analysis was performed according to Laemmli (22) with a10% acryl-
amide concentration for the separating gel . Each immunoprecipi-
tate was extractedby boiling for2min in the sample buffer (0.0625
M Tris-HCI, pH 6.8, containing 1% SDS, 10% glycerol, and
0.001% bromollhenol blue) with or without 1% (3-ME .
Magnesium Dependent Collagen or Laminin Binding Assays.
￿
96-
well microtiter plates (3915 ; Falcon Plastics, Cockeysville, MD) were
coated with either collagen type IV (fromhuman placenta, C-7521;
Sigma Chemical Co., St . Louis, MO)or laminin (frommouseEHS
sarcoma, 1,2020 ; Sigma Chemical Co.) by incubating the plates
overnight at 4°C with 100 11 of a collagen or laminin solution
(5 hg of protein per ml of PBS) . The plates were then rinsed to
remove the unbound protein and incubated with a 1% solution
ofBSA in PBS for 2 h at room temperature to saturate the surface
area of the plates with protein. A549 cells (4 x 106 cells/ml) were
added to the plate (200 Al of cell suspension per well in PBSwith
2 MM MgC12 for collagen binding and 8MM MgC12 for laminin
binding) . After 1 h at 37°C, nonadherent cells were removed by
washing the plates with PBS containing MgC12 . Thebound cells
were fixed by the addition of paraformaldehyde (3% in PBS) at
room temperature for 10 min and stained with a 1:1(vol/vol) mix-
ture of crystal violet (1% in methanol) andparaformaldehyde (3%
in PBS) for 3 min at room temperature. Afterwashing in PBS the
plates were air dried and the binding of cells to the immobilized
ligand was monitored photometrically at 540 nm usingan ELISA
plate reader as previously described (23), except with using crystal
violet (24) to stain cells instead of toluidine blue. Antibodies (5E8,
5C7, and 12F1) and soluble ligands (collagen and laminin) were
tested for their ability to inhibit the binding to either immobilized
collagen or lamininby adding the inhibitor (at the concentrations
indicated) to the cell suspension before and during the incubation
of the cellson the protein-coated microtiter plates.Thepercentage
of attachment was determined as follows : percent of attachment
= (ODSQ of binding with inhibitor - OD 5,o of nons
binding')/(ODaso ofmaximum binding# - OD 5oof nonspecific
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binding"`) ; where (') A549 cells bound to immobilized ligand in
absence ofMgC12; and (t) A549 cellsbound to immobilized ligand
in optimal concentration of MgC12 with no inhibitor.
VLA-2 a Chain Speck mRNA Analysis. A cDNA probe
c for theVLA2achain messagewas prepared from a plasmid
(2.721,) obtained from Dr. M. Hemler. The 2.721, plasmid con-
tainscDNA from base 1,792 to 5,373 (COON half of the coding
area andthe 3'-untranslated region) of VLA-2 ct chain gene (25) .
Escherichia coliDH5bacteria transformed with 2.72Lwere grown
under selection conditions, i.e., in Luria-Bertani medium (26) plus
ampicillin, and plasmidDNA extraction was done according to
a modified alkaline lysis procedure on a miniprep scale (27) . The
plasmid DNA was then precipitated by adding 0.6 volumes of
isopropanol and washed once with 70% (vol/vol) ethanol . The
plasmidDNA preparation was digested with two restriction en-
zymes EcoRl andBgll (Bethesda Research Laboratories), and the
DNAfragments were separatedon a 1% agarose gel .DNAin the
gelwas visualized by ethidium bromide staining (26) . The VLA-
a2 cDNA fragment was excised and theDNA was electroeluted
from the gel slice and ethanol precipitated (26) . The specificity of
this probe for VLA-a2 mRNA was established by a PCR and by
Northern blot analysis of mRNA derived from cells expressing
VLA-2 (A549) and cells on which VLA-2 is not detectable
(QU-DB).
For thePCR, purifiedcDNA from2.721, was mixedwith two
oligo-nucleotide primers that were designed based upon the pub-
lished sequence of the VLA-2 gene (25) . The 18mer and 20mer
primers were prepared by the DNA Synthesis Facility at RPCI
and were labeled at the 5'-end with T4 polynucleotide kinase in
the presence of [y>2P]ATP (7,000 Ci/mM) . Double-stranded
cDNA was synthesized and amplified 21 cycles in the presence of
DNA polymerase . The last five cycles were run with the labeled
primers and the labeledDNAwas extracted, ethanol precipitated,
subjected to electrophoresis, andthen exposed for autoradiography.
The resulting autoradiograph revealed a single oligonucleotideband
with the predicted size, i.e ., 465 bases .
For the Northern blot, total cellular RNA was isolated by
modification of the guanidinium monothiocyanate method of
Cathala et al . (28) . Briefly, A549 or QU-DB cells (3 x 108 cells)
or snap frozen lung tumor specimens or nontumor lung tissue
(2-6 geach) were lysed in 20-40 ml oflysis buffer containing 5M
guanidinemonothiocyanate, 10mM EDTA, 50mM Tris, pH 7.5,
and 8% (vol/vol) /3-ME . The lysis mixture was vigorously shaken
to obtain a clear solution . TotalRNAwas precipitated with 140-280
ml of 4M lithium chloride followed by incubation at 4°C, over-
night . The sample was transferred to 30-mlCorextubesandRNA
was sedimented by centrifugation at 11,000 g for 90 min . TheRNA
pellet in each tube wasresuspended in 10 ml of 3M lithium chlo-
ride to dissolve residual DNA and RNA and repelleted by cen-
trifugation at 11,000 g for 60 min . TheRNA pellet in each tube
was then dissolved in 10 ml of RNA solubilization buffer (0.1%
SDS, 1mM EDTA, and 10mM Tris, pH 7.5). The resulting solu-
tion was treated with 100 wg/ml proteinase K at 37°C for 2 h
followed by three extractions with equal volumes of phenol/chlo-
roform/isoamyl alcohol (25:24:1) . Theaqueous layerwas adjusted
to 100mM NaCl and theRNA precipitated with 2.5 volumes of
ethanol . Poly(A)* RNA was purified by affinity chromotography
on an oligo (dT) cellulose column (29) .
RNA samples were dot blotted onto nitrocellulose paper directly
for hybridization or were separated in a 1% agarose gel containing
formaldehyde (20mM boric acid,pH 8.3, 1mM EDTA, 3% form-
aldehyde) which was then dried for in situ agarose gel hybridiza-
tion as described (30) or stained with ethidium bromide.For ethidium bromide staining, the agarose gel containing the
RNA sample was sequentially soaked in 50mM NaOH, 0.5 M
Tris (pH7.0), and 0.5 ttg/ml ethidium bromide for 30 min each,
then exposed to an LTV light for fluorescence photography. The
RNA was probed using the 2.72LcDNA (described above) labeled
with '2P (31) . The dot blot hybridization technique was based
upon a previously reported protocol (32) and the in situ agarose
gel hybridization technique was a modification ofa protocol reported
by Ahmad et al . (30) in which we used SSC (0.15M NaCl, 0.015
M sodium citrate at pH 7.0) in lieu of SSPE (0.18 M NaCl, 10
mM NaPO 4 , 1 mM EDTA) .
Results
Lung Tumor-associated Antigen Identified AsA Noncovalently
Linked Heterodimeric Molecule. Previous reports identified a
cell surface molecule present on -75% of all human non-
small cell lung cancers that was not readily detectableon adult
normal human lung tissue . A previous report indicated that
this molecule was recognized by a mAb, 5E8, that immuno-
precipitates a single glycoprotein chain with an estimatedmo-
lecular mass of 160 kD (7) . Fig . 1 illustrates that at pH 7.0,
the 5E8 antibody consistently immunoprecipitates, from the
detergent lysate of surface iodinated lung tumor cell line A549,
a heterodimeric protein complex in nonreducing and reducing
gels (Fig. 1, A and C), and that incubation of the cell lysates
at either high pH (pH 11.5 ; see Fig. 1 E) or low pH (pH
4.5 ; data not shown) before immunoprecipitation results in
theprecipitation of only one ofthetwo proteins of this com-
plex, i.e., the heavier 160-kD molecule. The original conclu-
sion that gp160 consisted of a single polypeptide chain was
based upon the presence ofonly one major radiolabeled band
in the SDS gels of lung tumor cell lysates immunoprecipi-
tated with the mAb 5E8 (7) . However, in this original re-
port and in a subsequent report on gp160 (8), a second faster
migrating band was observed. One possibility was that this
second minor band with an estimated molecular mass of 130
kD was a proteolytic fragment of the larger protein. An al-
ternative explanation for the faster migrating protein observed
with the lung TAA was that gp160 was noncovalently as-
sociated with a second protein. Pursuant to this possibility
a careful review of the original labeling and immunoprecipi-
tation protocols revealed that the cell lysates were inadver-
tently exposed to low pH (a condition that could readily
dissociate noncovalently associated molecules) beforeimmuno-
precipitation . This lowpH (ti4.5) resulted from the vendor
of radioactive iodine (ICN) switching from using 0.1 N to
0.01N NaOH in the stock iodine preparation . Since investi-
gators were not aware of this change, they continued to add
equal volumes of 0.1 N HCl to neutralize the stock iodine
preparation before iodination of cells, which resulted in a 10-
fold excess of acid required to neutralize the new stock prep-
aration ofiodine thereby inadvertentlydissociating the 160-kD
and 130-kD polypeptide chains . It was concluded from the
results presented in Fig. 1 that the 5E8 antibody recognizes
a determinant on the 160-kD subunit, and that this larger
protein is noncovalently associated with a protein that mi-
grates faster in the gel . It was also noted that both bands
that are immunoprecipitated at a neutralpH migrate slightly
slower in reducing compared to nonreducing gels, an obser-
vation that is consistent with molecules that have multiple
intrachain disulfide bonded cysteines .
Lung Tumor-associated Molecule Comigrates with VLA-2 in
SDS-PAGE. The estimated molecular masses of the lung
tumor-associated heterodimer, i .e., 160 and 130kD in reducing
gels, and the faster migration patterns ofboth protein chains
in nonreducing gels was strikingly similar to that which had
been observed and reported for the heterodimeric collagen-
binding integrin VLA-2 which was originally detected on
a portion of normalhuman T lymphocytes following activa-
tion (33, 34) . Based upon these similarities, radioiodinated
cell lysates of A549 lung tumor cells were immunoprecipi-
tated with a mAb, 12111, which is specific for the a chain
of VLA2 (19) . Analysis of the labeled immunoprecipitates
in SDS-PAGE revealed two bands that were indistinguish-
able from the two bands immunoprecipitated by 5E8 both
in nonreducing and reducing gels (Fig . 1, compare lanes A
with B, and C with D) . As was observed with 5E8, the
antiVLA-2 ace antibody (12111) immunoprecipitated only
Figure 1.
￿
SDS-PAGE analysis of
surface iodinated A549 cell lysates
immunoprecipitated with mAbs
specific for gp160 (5E8) or VLA-2
a chain (12111) . Following immu-
noprecipitation with mAb 5E8
(lanes A, C, and E) and 12111 (B,
D, and F) the immunoprecipitates
were analysed : A andB, on a non-
reducing gel; C, D, E, and F, on
a reducing gel . All A549 cell lysates
were precleared by NMyG before
immunoprecipitation with mAb.
Celllysates analyzed inEandFwere
exposed topH 11 .5 for 30 min and
readjusted topH 7.0 before immu-
nopreapitation . All othercelllysates
were maintained at pH 7. Under
reducing conditions (lanes C and D) two bands at -160 and -130 kD are revealed, which run slightly faster under nonreducing conditions (lanes
A and B) . After exposure to high pH before immunoprecipitation (lanes E and F) only the higher molecular mass band is observed .
1113
￿
Chen et al .the 160-kD a chain when the cell lysates were first exposed
to high pH (Fig . 1 F) or low pH (data not shown), indi-
cating that the association of the ct chain ofVLA2 (and the
lung TAA) with the (3 chain is noncovalent and pH labile .
Sequential andReciprocal Immurtoprecipitations Support the No-
tion that TAA Heterodimer and VLA-2 Are the Same Molecule
Complex . The results presented in Fig. 1 were consistent
with the notion that VLA2 and the lung tumor-associated
molecular complex recognized by 5118 were either very similar
coexpressed molecules or that they were the same molecular
complexes. The latter possibility was previously suggested
by others (Hemler,M . E ., andC . Crouse, unpublished results,
see reference 25) . An attempt wasmade to resolve this ques-
tion by a sequential immunoprecipitation of surface iodinated
A549 cell lysates first with the TAA-specific antibody (5E8)
and subsequently with theVLA-2 ct chain-specific antibody
(12F1) . After immunoprecipitation ofA549 cell lysates with
5E8, we found that nothing further could be immunopre-
cipitated by 12F1 (see Fig. 2, lane 8) . The reciprocal sequen-
tial immunoprecipitation revealed the same result (Fig. 2, lane
11) . Densitometric scanning ofthe gel revealed that 5E8 elim-
inated97% and 12F1 eliminated93% ofthe VLA-2-likemol-
ecule. The elimination ofthe target molecule with either 5E8
or 12F1 suggested that these two antibodies were recognizing
the same molecular complex. The failure of a control mAb
(5C7) to eliminate the target molecule (Fig. 2, lanes 9 and
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10) confirmed the specificity of the sequential immunopre-
cipitation experiments .
VLA-2-like Complex on Lung Tumors Binds Collagen and
Laminin. Since the sequential immunoprecipitations estab-
lished that the tumor-associated molecular complex andVLA2
were serologically indistinguishable and their patterns of
migration in SDS gels identical, it was of interest to deter-
mine whether the VLA2-like molecule on human lung
tumors was also functionally similar to VLA2 expressed on
normal cells in terms of ligand binding. Previous studies
showed that VLA-2 binds to collagen (36, 37) or collagen
and laminin (37, 38) . We first established that the human
lung tumor cell line A549 binds to human collagen type IV
and laminin and that this binding is magnesium dependent
(data not shown) as has been reported for VLA-2 on normal
cells (39) . The data presented in Fig. 3 illustrate that 80%
of the binding of the tumor cells to collagen was inhibited
and -30% of the laminin binding was inhibited by the 5E8
mAb. This suggests that the majority of the collagen binding
and a smaller, but significant proportion ofthe laminin binding
by the lung tumor cells is mediated by the VLA-2-like mole-
cule . It is of interest that the 12F1 antibody which im-
munoprecipitates VLA-2 does not inhibit collagen or laminin
binding (Fig. 3A) suggesting that while thesetwo antibodies
both recognize determinants on the ot chain (Fig. 1, E and
F) only the 5E8 antibody recognizes a determinant within
Figure 2 .
￿
SDS-PAGE analysis ofsurface iodinated A549cell
lysates sequentially and reciprocally immunoprecipitatedwith
mAbs specific for gp160 (5118) or VLA-2 a chain (12F1) . In
lanes 1-6, surface iodinated cell lysates were first immuno-
precipitated with one ofthree mAbs : lanes 1 and 2, 5118 ; lanes
3 and 4, 5C7 (a control mAb) ; lanesSand6, 12F1. Two bands
at -160 and -130 kD are present in lanes 1, 2, 5, and 6 .
These bands are not present in lanes 3 and 4 . In lanes 7-12,
the supernatants from the first immunoprecipitations (lanes
1-6, respectively) were subjected to a second immunoprecip-
itation with either 5138 (lanes 7, 9, and 11) or 12F1 (lanes
8, 10, and 12) . With the exception oflanes 9 and 10, no specific
bands are observed in the reprecipitation protocol .U
ro
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A. Collagen coated plate
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B . Laminin coated plate
or close to the ligand binding site of this extracellular matrix
receptor. The failure of collagen or laminin in solution to
block the binding of these cells to the ligand immobilized
on plastic surfaces (Fig. 3, A and B) suggests that VLA2
has a much higher affinity for the immobilized ligand than
for the same molecule in solution .
VLA-2-like Molecule Over Expressed on Primary Lung
Tumors. Having established the presence of a molecular com-
plex on the surface ofhuman lung tumors that was indistin-
guishable from VLA2 (found on activatedT cells and platelets)
with regard to subunit structure, antigenicity and ligand
specificity, it was important to determine whether or not this
molecular complex was expressed by normalhuman lung tissue
and either over expressed or aberrantly expressed by neoplastic
lung tissue . Previous immunofluorescent and immunocyto-
chemical studies utilizing the 5E8 antibody revealed minimal
staining of normal adult human lung tissue (6), although
restricted areas of normal lung (primarily the terminal bron-
chial epithelium) did stain above background with the 5E8
antibody (7) . The data presented in Fig. 3, which indicate
that the 5E8 antibody binds to a determinant within or close
to the ligand binding site, cast some doubt on the conclu-
sions drawn from these previous studies since it is conceiv-
able that some or all of the VLA-2 combining sitesmay have
been occupied by the extracellular matrix ligand thereby
blocking the binding of the 5E8 antibody. Moreover, im-
munohistochemical studies ofVLA2 expression using an an-
tibody that recognizes a determinant on the a chain ofVLA2
outside of the collagen-binding site suggested that in addi-
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Inhibitor concentration (gghnl)
Figure 3 .
￿
Binding of A549 to immobilized collagen (A) or laminin (B) in the presence of various mAbs or soluble collagen or laminin. The optimal
magnesium concentration for A549 cell attachment to each ligand, 2 mM MgCl2 for collagen binding and 8mM for laminin binding, was first estab-
lished by a direct cell attachment assay.
tion to bronchial epithelium, the alveolar septa, a portion
of the type II pneumocytes and the mesothelial lining of the
pleura expressed staining levels for VLA-2 above background
(40) . Therefore, the question ofVLA-2 expression in normal
and neoplastic lung tissues was now focused upon the levels
of a2-specific mRNA in order to circumvent potential pit-
falls associated with immunofluorescence and immunocyto-
chemistry. A Northern hybridization analysis of poly(A)+
RNA extracted from two different gp160-positive human
tumor cell lines, A431 and A549 (using a 32P-labeled, VLA2
a-chain-specific cDNA probe 2.72L, an a2 cDNA subclone
fromEcoR1 site near base 1800 through end of 3'-untranslated
region of a2 cDNA clone 2.72 [reference 25]) identified a
single 7.3-kb band (Fig. 4A, lanes 1 and 3) . This same probe
did not hybridize with poly(A)+ RNA extracted from a
gp160-negative human lung tumor cell line, QU-DB (Fig.
4 A, lane 2) . These results further support the presence of
VLA2a chain on the gp160-positive human tumor cell lines,
and confirm the specificity of the cDNA probe 2.72L . Total
RNA extracted from (a) matched sets ofpatients' lung tumor
biopsies and normal lung tissue, and (b) gp160-positive and
-negative lung tumor cell lines, was dot blotted onto nitrocel-
lulose membranes and probed with the 32P-labeled cDNA
clone 2.72L . The probe hybridized toRNA from lung tumor
biopsy tissue and a gp160-positive lung tumor cell line, but
evidence of hybridization was not detectable with the RNA
from normal lung tissue or a gp160 negative lung tumor cell
line . Representative results are shown in Fig. 4 B . A positive
signal was observed with as little as 2 jig of lung tumorRNAFigure 4 .
￿
VLA-2 a chain-specific mRNA analysis. (A) Northern hybridization (in situ) . Poly(A)* RNA was separated in a 1% agarose gel and
hybridized in situ with the 32P-labeled VLA-2 a chaincDNA clone 2.72L . The poly(A) * RNA samples were extracted from: lane 1, A549 cells (VLA-
2*) ; 2, QU-DB cells (VLA-2 - ) ; 3, A431 cells (VLA-2') . One specific band at 7.3 kb is present in lanes 1 and 3, while absent in lane 2. (B) Dot
blot analysis of total cellularRNA probed with 32Rlabeled VLA-2 a chaincDNA clone 2.72L . The RNA was isolated from : (1) A549 cells ; (2) normal
lung tissue, (3) lung tumor tissue from the same patient as 2 ; (4) QU-DB cells ; (S) normal lung tissue from another patient. VLA-2 a chain-specific
mRNA is detected only in 1 and 3 .
and no positive signal was observed with as much as 10 Nig
ofRNA from normal lung . These same results have been
observed four times using matched sets of normal and neo-
plastic lung tissue. Based upon this data and upon the fact
that about four timesmoreRNA was extracted from a gram
oflung tumor than from a gram ofnormal adult lung tissue,
we estimate that lung tumors express at least twenty times
moreVLA-2 cx chain message than normal adult human lung
tissue.
Discussion
The results presented here establish that the overexpres-
sion ofVLA2 byhuman lung tumors represents a new lung
tumor-associated molecular complex with a well-defined
subunit structure and possible function. Previous studies have
illustrated that the overproduction of a molecule by human
tumors may represent a common cellular phenotypic change
that occurs as a function of cellular transformation . Carcinoem-
bryonic antigen (CEA) is a member of a family of cell sur-
face glycoproteins that are produced in excess in essentially
all human colon carcinomas (41) and in a high proportion
of carcinomas ofmany other sites, including lung (42, 43) .
These observations have led to the development ofextremely
useful diagnostic and prognostic clinical assays that arenow
used extensively in oncology . However, the functions and
possible significance of these tumor-associated molecules with
regard to malignant cell behavior have remained largely un-
known for many years. Recently, CEA was identified as an
intercellular adhesion molecule and the overproduction of this
molecule was postulated to be directly involved in colon car-
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cinogenesis either through effects on metastasis or on tissue
architecture (44) . Since evidence supports the notion that
integrin-matrix interactions facilitate the invasion of fibro-
blasts, lymphoid cells, and epithelial cells during wound
healing (45), it is tempting to speculate that the overexpres-
sion of an integrin such as VLA2 by human lung tumors
contributes to the tumor's ability to invade normal tissue and
to metastasize to other tissues. The association of increases
in certain a1 integrins with increases in tumorigenicity has
been reported for human osteosarcomas (46) and the 03 inte-
grin subunit was found to be strongly expressed by human
malignant melanomas, but not in benign melanocytes (47,
48) . The potential importance of integrin-mediated adher-
ence in the metastasis of tumors is also illustrated by the ability
of RGD-containing peptides, which inhibit the binding of
many integrins to their extracellular matrix ligands (49) to
reduce the number of metastatic nodules found within the
lungs of mice injected with B16F10melanoma cells (50) and
the inhibition of the movement of human melanoma cells
through an amnionic basement membrane (51) . These findings
and the information presented here provide an opportunity
and a rationale to explore the role ofVLA2 in the pathogen-
esis of human lung cancer.
The data presented here are the first to demonstrate the
overproduction of an integrin by primary human lung tumors.
While these data have not causally linked the overexpression
ofVLA-2 to tumor invasion or metastasis in view of the ex-
perimental data linking integrins to tumor growth, it is rea-
sonable to postulate that their overexpression in lung tumors
is associated with tumor progression . One of the initial andrequisite steps in tumor invasion involves the tumor cell's
penetration throughabasement membrane. This step requires
the attachment of the neoplastic cell to components of the
basement membrane, primarily lamininand type IV collagen .
These two molecules are recognized as ligands for VLA-2
on normal cells (39) and are demonstrated here to be ligands
that arebound by theVLA2-like molecule on human lung
tumors . The role of VLA-2 (as well as other integrins) in
the pathogenesis oftumor must now be addressed directly
by the comparison of VLA2-positive and VLA2-negative
variants ofhuman lung tumors for their tumorigenicity in
immunodeficient mice. The role of these integrins may also
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be addressed by gene transfer, followed by analysis of inva-
siveness, metastasis, and homing of cells after the cells' en-
graftment into immunodeficient mice. Thefinding that human
lung tumor cell lines (52) as well as human lung tumorbi-
opsies (53) canbe engrafted into theCR17-SCID mousemake
such experiments entirely feasible. Theobservation that after
implantations ofSCID mice withtumorbiopsy pieces, mice
are coengrafted with the tumor and the infiltrating leuko-
cytes (54) opens the possibility ofinvestigating the complex
and interactive role of integrins on the tumor and host im-
munocompetent cells in the progression of a tumor in vivo.
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